35 citations
,
April 2013 in “Sexual medicine reviews” 5-alpha reductase inhibitors slightly increase the risk of sexual and mood side effects, and breast growth in men.
January 2005 in “Metas de Enfermería” Serenoa repens may help with prostate issues, but more research is needed to confirm its effectiveness.
These medications for BPH have known risks and may have new side effects.
1 citations
,
January 2017 in “Journal of Clinical Trials & Patenting” The lotion safely and effectively reduces unwanted hair growth.
October 2015 in “Annals of Internal Medicine” Dutasteride, fesoterodine, and finasteride help older patients with urinary issues.
1 citations
,
January 2010 in “Elsevier eBooks” Testosterone therapy may help men with osteoporosis.
September 2004 in “Inpharma Weekly”
49 citations
,
January 1994 in “The Journal of Steroid Biochemistry and Molecular Biology” RU 58841 may treat acne, hair loss, and excessive hair growth.
November 2005 in “The Journal of Urology”
44 citations
,
October 2010 in “BJUI” 5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.
March 2026 in “The Aging Male” PDE5 inhibitors cause earlier adverse events in BPH treatment, requiring careful monitoring.
January 2023 in “DIGITAL HEALTH” Most men using teledermatology for hair loss treatment saw improved hair and self-esteem, with some experiencing side effects.
These medications for BPH have known risks and may have new side effects.
26 citations
,
January 2005 in “PubMed” RUM-loaded SLN shows promise for treating acne and hair loss topically.
February 2018 in “The Journal of Sexual Medicine” Natesto nasal gel improves erectile function and mood in men with low testosterone within 30 days.
1 citations
,
September 2023 in “Prostate International” Cervi Parvum Cornu complex improved urinary symptoms in men without major side effects.
11 citations
,
December 2018 in “Assay and Drug Development Technologies” Natural herbal compounds might treat certain medical conditions by reducing DHT levels, but more research is needed to confirm their effectiveness and safety.
February 2025 in “Iranian journal of pharmaceutical research” May 2025 in “Reactions Weekly” October 2022 in “Zenodo (CERN European Organization for Nuclear Research)” EndoPump Male Enhancement lacks proven effectiveness and may pose health risks.
January 2008 in “xPharm: The Comprehensive Pharmacology Reference”
98 citations
,
August 2004 in “BJU international” Medications have become the main treatment for enlarged prostate symptoms, replacing surgery and watchful waiting.
2 citations
,
August 2013 in “The Lancet. Diabetes & endocrinology” The FDA rejected a testosterone drug again due to safety concerns.
June 2023 in “Sri Lanka Journal of Menopause”
April 2016 in “The Journal of Sexual Medicine”
1 citations
,
December 2023 in “Curēus” Tadalafil is effective for treating urinary symptoms in men with BPH.
July 2005 in “SKINmed/Skinmed” BRL 7660, once studied for male contraception, showed promise as an acne treatment but was not developed further due to competing drugs.
8 citations
,
April 2004 in “The Journal of Urology” Doxazosin and finasteride negatively affect sexual function in men with BPH.
111 citations
,
June 2015 in “Age and Ageing” Dutasteride, fesoterodine, and finasteride are beneficial for older patients, while most other drugs should be used cautiously or avoided.
July 2010 in “PharmacoEconomics & Outcomes News”